Clinical Trials Browser

Interventional × Leiomyosarcoma × Temozolomide × Clear all

NCT04200443 2026-05-01

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Phase 2 Active not recruiting

96 enrolled 15 charts

Leiomyosarcoma, Sarcoma

NCT05204524 2022-01-24

Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma

Phase NA Unknown

Leiomyosarcoma

NCT00003718 2014-01-06

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

Phase 2 Unknown

GynecologicSarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Endometrial Neoplasms, Sarcoma, Endometrial Stromal, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00033709 2014-01-06

Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma

Phase 2 Unknown

Leiomyosarcoma, Sarcoma